Adverse Event Clinical Research
1.0.1 - STU1 International flag

This page is part of the Adverse Event Clinical Research (v1.0.1: STU 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

MedicationRequest: Medication Request for bresentrik

Page standards status: Informative

Generated Narrative: MedicationRequest

Resource MedicationRequest "medicationrequest-for-bresentrik"

identifier: http://www.bmc.nl/portal/medstatements/1234568900-studyDrug (use: official)

status: active

intent: order

Medications

-Reference
*Medication/bresentrik: bresentrik 2mg tablet

subject: Patient/JanetPatient: Janet " CLINICAL TRIAL PATIENT"

supportingInformation: ResearchStudy/BreastCancerTrial: http://baseUrlOfHospitalHolding/PlanDefinition/protocol-for-the-ResearchStudy

authoredOn: 2023-04-05

requester: : Could be reference to inline contained profile such as Reference(practitioner-1) Ronald Bone, MD

Reasons

-Concept
*Breast Cancer (SNOMED CT#254837009)

dosageInstruction

sequence: 1

text: 6 mg PO daily for remission induction; adjust dosage to white blood cell (WBC) count. With hold treatment if WBC is less than 15,000/µL; resume when WBC is greater than 50,000/µL

timing: Once per 1 days

route: Oral route (qualifier value) (SNOMED CT#26643006)

doseAndRate

dispenseRequest

numberOfRepeatsAllowed: 1

quantity: 600 mg (Details: UCUM code mg = 'mg')

ExpectedSupplyDurations

-ValueUnitSystemCode
*30daysUnified Code for Units of Measure (UCUM)d